肾移植与抗人巨细胞病毒感染的新药研发新进展

Abstract
Figure/Table
References (0)
Related Citation (15)

［1］GondranTellier B, Baboudjian M, Lechevallier E, et al. Renal transplantation, for whom, why and how?［J］. Prog Urol, 2020, 30(15): 976-981.

［2］AbouJaoudé M, El Hage S, Akiki D, et al. Cytomegalovirus infection in kidney transplant patients: Prevalence, risk factors, and impact on outcomeA local multicentre experience［J］. Transpl Immunol, 2021, 69: 101473.

［3］Zuhair M, Smit GSA, Wallis G, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and metaanalysis［J］. Rev Med Virol, 2019, 29(3): e2034.

［4］Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients［J］. Am J Transplant, 2009, 9: S1-S155.

［5］Gerna G, Lilleri D, Human cytomegalovirus (HCMV) infection/reinfection: development of a protective HCMV vaccine［J］. New Microbiol, 2019, 42(1): 1-20.

［6］Hkeberg I, Eriksson BM, ZweygbergWirgart B, et al. Diagnostic markers and risk factors of cytomegalovirus infection anddisease in renal allograft recipients［J］. Scand J Infect Dis, 1995, 27(5): 435-440.

［7］Gerna G, Lilleri D, Baldanti F. An overview of letermovir: a cytomegalovirus prophylactic option［J］. Expert Opin Pharmacother, 2019, 20(12): 1429-1438.

［8］Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients［J］. Clin Infect Dis, 2002, 34(8): 1094-1097.

［9］Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus［J］. J Pathol, 2015, 235(2): 288-297.

［10］Eddleston M, Peacock S, Juniper M, et al. Severe cytomegalovirus infection in immunocompetent patients［J］. Clin Infect Dis, 1997, 24(1): 52-56.

［11］Parsons AJ, Cohen T, Schwarz TM, et al. Valspodar limits human cytomegalovirus infection and dissemination［J］. Antiviral Res, 2021, 193: 105124.

［12］Atabani SF, Smith C, Atkinson C, et al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy［J］. Am J Transplant, 2012, 12(9): 2457-2464.

［13］Poole E, Sinclair J. Understanding HCMV latency using unbiased proteomic analyses［J］. Pathogens, 2020, 9(7): 590.

［14］Perera MR, Wills MR, Sinclair JH. HCMV antivirals and strategies to target the latent reservoir［J］. Viruses, 2021, 13(5): 817.

［15］Bednar C, Ensser A. CARsA new perspective to HCMV treatment［J］. Viruses, 2021, 13(8): 1563.

［16］Bogner E, Egorova A, Makarov V. Small moleculesprospective novel HCMV inhibitors［J］. Viruses, 2021, 13(3): 474.

［17］Fantus D, Thomson AW. Evolving perspectives of mTOR complexes in immunity and transplantation［J］. Am J Transplant, 2015, 15(4): 891-902.

［18］Imlay HN, Kaul DR. Letermovir and maribavir for the treatment and prevention of cytomegalovirus infection in solid organ and stem cell transplant recipients［J］. Clin Infect Dis, 2021, 73(1): 156-160.

［19］Hawks KG, Fegley A, Sabo RT, et al. High dose valacyclovir for cytomegalovirus prophylaxis following allogeneic hematopoietic cell transplantation［J］. J Oncol Pharm Pract, 2023, 29(1): 130-137.

［20］Ko EJ, Yu JH, Yang CW, et al. Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after antithymocyte globulin as rejection therapy［J］. Korean J Intern Med, 2019, 34(2): 375-382.

［21］Kapoor A, Ghosh AK, Forman M, et al. Validation and characterization of five distinct novel inhibitors of human cytomegalovirus［J］. J Med Chem, 2020, 63(8): 3896-3907.

［22］Leowattana W. Antiviral drugs and acute kidney injury (AKI)［J］. Infect Disord Drug Targets, 2019, 19(4): 375-382.

［23］Tasoujlu M, Khalafkhany D, Makhdoomi K, et al. Cytomegalovirus UL97 ganciclovir resistance mutations in kidney transplant recipients［J］. Bratisl Lek Listy, 2022, 123(7): 518-522.

［24］Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory cytomegalovirus infections with or without resistance posttransplant: results from a phase 3 randomized clinical trial［J］. Clin Infect Dis, 2022, 75(4): 690-701.

［25］Frange P, LeruezVille M. Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections［J］. Med Mal Infect, 2018, 48(8): 495-502.

［26］Faure E, Galperine T, Cannesson O, et al. Case report: Brincidofovirinduced reversible severe acute kidney injury in 2 solidorgan transplant for treatment of cytomegalovirus infection［J］. Medicine (Baltimore), 2016, 95(44): e5226.

［27］El Helou G, Razonable RR. Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidencebased review［J］. Infect Drug Resist, 2019, 12: 1481-1491.

［28］Marschall M, Stamminger T, Urban A, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses［J］. Antimicrob Agents Chemother, 2012, 56(2): 1135-1137.

［29］Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoieticcell transplantation［J］. N Engl J Med, 2017, 377(25): 2433-2444.

［30］Wild M, Kicuntod J, Seyler L, et al. Combinatorial drug treatments reveal promising anticytomegaloviral profiles for clinically relevant pharmaceutical kinase inhibitors (PKIs)［J］. Int J Mol Sci, 2021, 22(2): 575.

［31］Adfeldt R, Schmitz J, Kropff B, et al. Diazadispiroalkane derivatives are new viral entry inhibitors［J］. Antimicrob Agents Chemother, 2021, 65(4): e02103-e02120.

［32］Roy S, Kapoor A, Zhu F, et al. Artemisinins target the intermediate filament protein vimentin for human cytomegalovirus inhibition［J］. J Biol Chem, 2020, 295(44): 15013-15028.

［33］Paramonova MP, Khandazhinskaya AL, Ozerov AA, et al. Synthesis and antiviral properties of 1substituted 3［ω(4Oxoquinazolin4(3H)yl)alkyl］ uracil derivatives［J］. Acta Naturae, 2020, 12(3): 134-139.

［34］Hutterer C, Hamilton S, Steingruber M, et al. The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitors［J］. Antivir Res, 2016, 134: 130-143.